Legacy Capital Group California Inc. Buys Shares of 7,389 Boston Scientific Corporation $BSX

Legacy Capital Group California Inc. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 7,389 shares of the medical equipment provider’s stock, valued at approximately $721,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Orleans Capital Management Corp LA bought a new stake in Boston Scientific in the third quarter worth $668,000. Intellectus Partners LLC acquired a new stake in shares of Boston Scientific in the third quarter worth about $490,000. Aptus Capital Advisors LLC lifted its position in shares of Boston Scientific by 507.9% in the third quarter. Aptus Capital Advisors LLC now owns 75,862 shares of the medical equipment provider’s stock worth $7,406,000 after buying an additional 63,382 shares during the last quarter. One Wealth Capital Management LLC bought a new stake in shares of Boston Scientific during the 3rd quarter worth about $436,000. Finally, Orion Porfolio Solutions LLC increased its holdings in shares of Boston Scientific by 60.0% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 58,486 shares of the medical equipment provider’s stock valued at $5,710,000 after acquiring an additional 21,936 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Boston Scientific Stock Performance

BSX opened at $71.24 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average price is $85.03 and its two-hundred day moving average price is $94.55. The firm has a market capitalization of $105.71 billion, a P/E ratio of 36.72, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. Boston Scientific Corporation has a 12-month low of $70.75 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the business earned $0.70 earnings per share. Boston Scientific’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Robert W. Baird lowered their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Mizuho dropped their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Needham & Company LLC decreased their price objective on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Finally, Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.36.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.